Mesuximide Explained

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

Medical use

is indicated for the control of absence seizures that are refractory to other drugs.

Notes and References

  1. Web site: Pfizer AG . 2005 . Petinutin (Mésuximide) . Official Pfizer AG Website . August 21, 2006 . fr . dead . https://web.archive.org/web/20050422010830/http://www.pfizer.ch/internet/fr/home/products/central_nervous_system/epilepsy/petinutin_mesuximid.html . April 22, 2005 .
  2. Web site: Pfizer Inc. . 2008 . Celontin (methsuximide capsules, USP) . Official Pfizer Inc. Website . November 21, 2014 .
  3. Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ . Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy . Neurology . 29 . 11 . 1509–13 . November 1979 . 116142 . 10.1212/wnl.29.11.1509 . 43643797 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mesuximide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.